Harmony Biosciences (HRMY)
(Real Time Quote from BATS)
$33.86 USD
+0.31 (0.92%)
Updated Aug 8, 2024 03:44 PM ET
After-Market: $33.98 +0.12 (0.35%) 4:06 PM ET
4-Sell of 5 4
B Value B Growth F Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
HRMY 33.86 +0.31(0.92%)
Will HRMY be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for HRMY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for HRMY
Harmony Biosciences Holdings, Inc. (HRMY) Surpasses Q2 Earnings and Revenue Estimates
HRMY or REGN: Which Is the Better Value Stock Right Now?
HRMY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Analysts See a 32.82% Upside in Harmony Biosciences (HRMY): Can the Stock Really Move This High?
Are Investors Undervaluing Harmony Biosciences (HRMY) Right Now?
MannKind Corporation (MNKD) Hit a 52 Week High, Can the Run Continue?
Other News for HRMY
Harmony Biosciences Holdings (HRMY) Receives a Buy from Oppenheimer
HRMY Stock Earnings: Harmony Biosciences Beats EPS, Beats Revenue for Q2 2024
Harmony Biosciences Holdings, Inc. 2024 Q2 - Results - Earnings Call Presentation
Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (BMRN), Elevation Oncology (ELEV) and Harmony Biosciences Holdings (HRMY)
Buy Rating Affirmed for Harmony Biosciences on Strong Earnings and Promising Drug Formulation Prospects